SAGE Therapeutics, Inc.

... ...
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
HZNPHorizon Therapeutics Plc 0.00%78.915.6%$205.00m
VRXValeant Pharmaceuticals International, Inc. 0.00%26.4114.1%$155.40m
CTLTCatalent, Inc. -0.26%115.002.1%$113.43m
BHCBausch Health Cos., Inc. 0.00%26.410.0%$90.94m
JAZZJazz Pharmaceuticals Plc 0.00%165.812.4%$87.34m
UTHRUnited Therapeutics Corp. 0.00%167.2614.1%$64.76m
SAGESAGE Therapeutics, Inc. 0.90%97.637.6%$58.81m
ACSTAcasti Pharma, Inc. 1.12%0.640.2%$53.37m
GWPHGW Pharmaceuticals Plc 1.37%139.726.1%$49.06m
AMRNAmarin Corp. Plc 0.16%6.141.5%$47.57m
PRGOPerrigo Co. Plc 0.16%44.726.8%$47.42m
ISRIsoRay, Inc. 6.84%2.032.5%$46.22m
ICLRICON plc 0.00%210.664.2%$42.89m
PCRXPacira Biosciences, Inc. 0.00%77.1610.0%$38.41m
ENDPEndo International Plc 0.69%7.278.7%$38.32m

Company Profile

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.